By Karen Roman
Candel Therapeutics, Inc. (Nasdaq: CADL) said it appointed Mark Sims as Chief Commercial Officer effective July 6, 2026, having previously served at AstraZeneca as Vice President and Global Franchise Head, where he directed the commercial strategy for one of the company’s largest business franchises.
Mr. Sims will lead the commercial strategy and launch readiness for the company’s Biologics License Application submission in the fourth quarter of 2026 and estimated 2027 launch of aglatimagene besadenovec, its localized prostate cancer treatment.
Never Miss our Weekly Highlights HERE
“We believe that intermediate- to high-risk localized prostate cancer represents a large and well-defined market opportunity, with approximately 65,000 patients diagnosed annually in the United States who are candidates for radiotherapy-based treatment approaches with curative intent,” said Paul Peter Tak, M.D., Ph.D., FMedSci, Candel’s President and CEO. “Mr. Sims has led and scaled some of oncology’s most significant franchises, and we believe his deep experience bringing innovative therapies to market will be instrumental to making aglatimagene, if approved, available to patients.”
READ MORE
VERAXA Biotech Expands R&D Hub in Heidelberg as Programs Advance Towards Clinical Development
Mr. Sims has over 25 years of experience in building and advancing global and national cancer franchises, having previously served at AstraZeneca, Novartis Idenix Pharmaceuticals, and Merck & Co. Inc., the company stated.
Mark Sims holds an MBA from the Thunderbird School of Global Management, Arizona State University and a Bachelor of Commerce from McMaster University.
Contact:
Click HERE to follow us on LinkedIn
